AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23065050
Drug: Both Whitacre
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Whitacre and Quincke needles with 1.2 ml of 0.5% plain bupivacaine
Trial: 22256634
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (Glucosamine Hydrochloride capsules, 2 capsules, 3 times per day)
Trial: 19301989
Drug: Tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol IR (50 or 100 mg, q4-6h, p.o.)
Trial: 19301989
Drug: Oxycodone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone IR (10 or 15 mg, q4-6h, p.o.)
Trial: 16702891
Drug: Pagoclone (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagoclone (4.8 mg)
Trial: 16702891
Drug: Pagoclone (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pagoclone (1.2 mg)
Trial: 16702891
Drug: Diazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (30 mg)
Trial: 15349004
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75 to 225 mg/d)
Trial: 11392066
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg chlorpheniramine (CPM) before surgery (Control group C, n = 22)
Trial: 11392066
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg dextromethorphan (DM) and 20 mg CPM before surgery (group B, n = 22)
Trial: 9034938
Drug: nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 300 mg b.i.d. (N2)
Trial: 9034938
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg b.i.d. (R2)
Trial: 9034938
Drug: nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nizatidine 300 mg q.h.s. (N1)
Trial: 9034938
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg q.h.s. (R1)
Trial: 1325613
Drug: rHuEpo at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo at an initial dose of 50 U/kg thrice weekly, adjusted to maintain Hb 105-120 g/l (group 1)
Trial: 1325613
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose of rHuEpo adjusted to maintain Hb 105-120 g/l (group 2)
Trial: 1325613
Drug: rHuEpo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo therapy (both groups)
Trial: 1325613
Drug: rHuEpo therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo therapy (group 1)
Trial: 26088854
Drug: Restrictive volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive volume of intraoperative fluid (≤8 mL/kg/h)
Trial: 26088854
Drug: Liberal volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal volume of intraoperative fluid (>8 mL/kg/h)
Trial: 23819476
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus additional early initiation of secondary prevention drugs (blood-pressure lowering protocol, simvastatin 40 mg, dipyridamole 200 mg m/r bd)
Trial: 23819476
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (initiation of aspirin and referral to a TIA clinic)
Trial: 16173864
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) with homework assignments
Trial: 12695287
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg BID)
Trial: 7751429
Drug: Indenolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indenolol (120 mg)
Trial: 2208416
Drug: Xintongkang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xintongkang capsule
Trial: 2208416
Drug: Persantin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persantin and aspirin (Control)
Trial: 27710700
Drug: Pharmacotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy and weight-bearing and balance-training exercises (Control)
Trial: 21256048
Drug: Tadalafil 40
RxNorm normalized name: tadalafil 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 40 mg add-on to bosentan
Trial: 21256048
Drug: Tadalafil monotherapy
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil monotherapy and as add-on
Trial: 19120729
Drug: Suction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suction of oral secretion before each positional care
Trial: 2126475
Drug: Natural porcine
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natural porcine surfactant treatment
Trial: 18254487
Drug: Parecoxib, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib, 40 mg
Trial: 16494640
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of ramipril 2.5 mg/felodipine ER 2.5 mg
Trial: 10764312
Drug: Systemic corticosteroid
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroid treatment arm
Trial: 10764312
Drug: Treatment failure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failure (defined as death, intubation, readmission for COPD, or intensification of drug therapy)
Trial: 17634903
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tropisetron intravenously for 5 days
Trial: 11590553
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) with estradiol 2 mg/day for 10 weeks
Trial: 17199783
Drug: Valproate +
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate + Carbamazepine (combined therapy)
Trial: 17199783
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment (>10 years) with Valproate, Carbamazepine, and combined therapy
Trial: 12644958
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg/h, continuous IV infusion for 5 hours)
Trial: 12644958
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution, equal volume for 5 hours)
Trial: 3510043
Drug: Barium suspension
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium suspension with optimal viscosity (suspended with 65-70 ml water)
Trial: 3510043
Drug: Barium suspension
RxNorm normalized name: barium
DrugBank: Barium (DB12481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barium suspension with high viscosity (same batch number, suspended with different water amounts)
Trial: 27163500
Drug: Belimumab 200
RxNorm normalized name: belimumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab 200 mg subcutaneously via autoinjector
Trial: 27163500
Drug: Belimumab 200
RxNorm normalized name: belimumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab 200 mg subcutaneously via prefilled syringe
Trial: 23028241
Drug: 0.5% lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% lidocaine, 10 mL (Group I)
Trial: 23028241
Drug: 9 mL
RxNorm normalized name: ethanol 6.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mL of 0.5% lidocaine mixed with 1 mL of 6 mg of nonparticulate betamethasone (Group II)
Trial: 16128861
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg acarbose
Trial: 16128861
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g saccharose
Trial: 1101231
Drug: Systematic psychologic
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic psychologic preparation and continued supportive care
Trial: 1101231
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no systematic psychologic preparation and supportive care)
Trial: 22043310
Drug: Patient administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient administered measures (Shared Decision Making Questionnaire, Control Preference Scale & Decisional Conflict Scale)
Trial: 22043310
Drug: Patient administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient administered measures
Trial: 12716672
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 14 mg . kg(‐)(1) . d(‐)(1)
Trial: 12716672
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 15 mg . kg(‐)(1) . d(‐)(1)
Trial: 10737537
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor cell vaccine (AV) plus bCG with sequential administration of IFN gamma and IFN alpha
Trial: 31379195
Drug: Olanzapine disintegrating
RxNorm normalized name: olanzapine Disintegrating Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine disintegrating tablets at a dose of 5 mg
Trial: 20670088
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of different allergens for 24 months
Trial: 20670088
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of different allergens for 18 months
Trial: 12956739
Drug: MPL-adjuvanted grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPL-adjuvanted grass pollen allergy vaccine
Trial: 9354313
Drug: TAK-044 25
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-044 25 mg
Trial: 9354313
Drug: TAK-044 50
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-044 50 mg
Trial: 9354313
Drug: TAK-044 100
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-044 100 mg
Trial: 1342112
Drug: Chloroquine 50
RxNorm normalized name: chloroquine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 50 mg/Kg
Trial: 1342112
Drug: Chloroquine 25
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 25 mg/Kg
Trial: 3007066
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A administration
Trial: 29577826
Drug: Effective pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective pain treatment
Trial: 19242897
Drug: Experimental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group (EG) - group therapy consisting of psychoeducation, cognitive restructuring, stress management, relaxation and mindfulness techniques.
Trial: 19242897
Drug: Experimental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group (EG) - group therapy.
Trial: 18055982
Drug: Daily deferiprone
RxNorm normalized name: Twice-Daily deferiprone 1000 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily deferiprone (DFP) 75 mg/kg plus desferrioxamine (DFO) 40-50 mg/kg twice weekly
Trial: 18055982
Drug: Daily deferiprone
RxNorm normalized name: Twice-Daily deferiprone 1000 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily deferiprone (DFP) monotherapy
Trial: 18055982
Drug: Desferrioxamine (DFO)
RxNorm normalized name: DFO
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (DFO) 40-50 mg/kg 5 days weekly (reference group)
Trial: 16581423
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (Lucentis) at doses ranging from 0.3 to 2.0 mg, administered via 5, 7, or 9 intravitreal injections at 2- or 4-week intervals for 16 weeks.
Trial: 2863148
Drug: Metoprolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (15 mg intravenous followed by 200 mg daily oral for 15 days)
Trial: 29956886
Drug: Control VOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control VOO (80 mg kg‐1)
Trial: 29956886
Drug: FVOO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVOO (500 mg kg‐1)
Trial: 29956886
Drug: FVOOT (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FVOOT (500 mg kg‐1; 1:1)
Trial: 20222114
Drug: CE-guided corticosteroid
RxNorm normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE-guided corticosteroid injection
Trial: 20222114
Drug: Accurate injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accurate injections
Trial: 19100058
Drug: Nadroparin 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 0.075 ml/10 kg (group I, n = 120)
Trial: 19100058
Drug: Nadroparin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 0.1 ml/10 kg (group II, n = 116)
Trial: 15812629
Drug: ITBV guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITBV guided fluid therapy
Trial: 15812629
Drug: CVP guided
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CVP guided fluid therapy
Trial: 12529074
Drug: Recent drinking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent drinking history (RDH) measured using daily diary and timeline followback methods
Trial: 8953876
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (0.2 mg) after combined spinal-epidural anesthesia (CSE group)
Trial: 8953876
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (0.2 mg) after general anesthesia combined with epidural anesthesia (EPI + GEN group)
Trial: 6977837
Drug: Acetylsalicylic acid,
RxNorm normalized name: Acetylsalicylic Acid, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid, 1 gm daily, and anticoagulants
Trial: 6977837
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic drugs
Trial: 25595470
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment in acute decompensated heart failure (specific diuretic details not provided).
Trial: 23279139
Drug: Aggressive heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive heart failure therapy
Trial: 21976561
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination treatment
Trial: 12899797
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (1-2 cycles of cisplatinum-based regimen)
Trial: 12899797
Drug: Post-operative chemotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative chemotherapy (2-4 cycles of cisplatinum-based regimen)
Trial: 12899797
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (1-2 cycles) in stage II NSCLC
Trial: 12899797
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to pre-operative chemotherapy
Trial: 12899797
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no pre-operative chemotherapy)
Trial: 11885179
Drug: 3+ mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3+ mm diameter implants
Trial: 11885179
Drug: 4+ mm
RxNorm normalized name: NEEDLE,PEN 31G,4MM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4+ mm diameter implants
Trial: 11885179
Drug: 7 mm
RxNorm normalized name: potassium 7.7 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mm length implants
Trial: 11885179
Drug: 16 mm
RxNorm normalized name: human regenerative tissue mtrx 16 mm TOPICAL SHEET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mm length implants
Trial: 8614498
Drug: 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg gadolinium-DTPA (standard dose)
Trial: 8614498
Drug: 0.3 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mmol/kg gadolinium-DTPA (triple dose)
Trial: 1410165
Drug: Self-administered smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered smoking re-exposure (smoking five cigarettes)
Trial: 2856773
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg once daily
Trial: 27824237
Drug: Focal extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal extracorporeal shock wave therapy (f‐ESWT) plus supervised eccentric training (SET) of the shoulder abductor muscles
Trial: 27824237
Drug: Focal extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal extracorporeal shock wave therapy (f‐ESWT) only
Trial: 27619826
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First + Assertive Community Treatment (HF+ACT)
Trial: 19010976
Drug: Verbal threat
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal threat condition; specific details on dosage and duration not available.
Trial: 19010976
Drug: Baseline condition;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline condition; specific details on dosage and duration not available.
Trial: 11505247
Drug: Complementary therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary therapies (CTs) course for nursing assistants
Trial: 3048103
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs together
Trial: 31901945
Drug: Outpatient acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient acceptance and commitment therapy (O‐ACT)
Trial: 28533306
Drug: Bendamustine-rituximab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine-rituximab combination therapy
Trial: 25908462
Drug: COSSACS -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COSSACS - Continuation of prestroke antihypertensive therapy
Trial: 22590838
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Metformin (500 mg tablets, two per twelve hours)
Trial: 22590838
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + Metformin
Trial: 16905220
Drug: Glycyrrhizin (6x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (6x weekly)
Trial: 16905220
Drug: Glycyrrhizin (3x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (3x weekly)
Trial: 16905220
Drug: Glycyrrhizin (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (once weekly)
Trial: 16905220
Drug: Glycyrrhizin treatment
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin treatment
Trial: 31798953
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (hand osteoarthritis education, assistive devices, CMCJ orthoses, and exercises)
Trial: 29974634
Drug: Aspirin as
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin as an adjunct to compression therapy
Trial: 21322823
Drug: Rivastigmine therapy
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine therapy
Trial: 12182952
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of glucose